Commentary reports on the IARC's cancer classifications, highlighting glyphosate and aspartame controversies.
Summary This article focuses on the Monographs Program, established to address the growing need for cancer classifications of chemicals and other agents. Part I provides an overview of the Program, its global impact, and how International Agency for Research on Cancer’s (IARC) cancer classifications are relied on by U.S. regulatory agencies. Part II discusses two controversial cancer classification decisions involving glyphosate and aspartame, both of which serve to showcase the Monographs Program’s persistent and controversial decision-making process. Indeed, the Program’s cancer classifications continue to roil U.S. federal agencies.
No takes yet. Share an insight, caveat, or question.
David B. Fischer (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: